1. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Issue 10 (October 2017) Authors: Pavel, Marianne E; Singh, Simron; Strosberg, Jonathan R; Bubuteishvili-Pacaud, Lida; Degtyarev, Evgeny; Neary, Maureen P; Carnaghi, Carlo; Tomasek, Jiri; Wolin, Edward; Raderer, Markus; Lahner, Harald; Valle, Juan W; Pommier, Rodney; Van Cutsem, Eric; Tesselaar, Margot E T; Fave, Gianfranco Delle... Journal: Lancet oncology Issue: Volume 18:Issue 10(2017:Oct.) Page Start: 1411 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗